Wikipedia

Probio DR10

brand name of a strain of microorganism

Probio DR10TM~, is a probiotic strain by Fonterra Research Development Centre (FRDC), patented and commercialised in the 1990s following the screening of over 2,000 strains.[1][2]

The strain involved is a lactic acid bacterium of Bifidobacterium lactis, originally isolated from yoghurt.[3] The publication of complete genomic sequence in 2018 has enabled the implementation of strict measures to ensure the control of product quality, safety and purity of the B. lactis HN019 strain.[3][4]

The Probio DR10TM~ strain is available in a range of finished formats, providing it with great potential to be applied across the food and beverage, dietary supplement, and pharmaceutical industries.[4]Bifidobacterium lactis is found in AnmumTM Materna and AnmumTM Essential Gold in the Malaysian market.

Benefits of Probio DR10TM~ change

Studies on Probio DR10TM~ indicate positive effects on various aspects of the digestive system.[4] These include:

Immune system support

In a randomised controlled trial (RCT) conducted with children aged 1 to 3 years, it was found that the incidence of high fever and severe acute lower respiratory infections was reduced by 5% and 35% respectively, in children who received Probio DR10TM~ along with a prebiotic, in comparison to those who were administered a placebo.[5]

A separate RCT also showed that the supplementation of Probio DR10TM~ in children aged 2 to 5 years reduced the incidence of diarrhea and fever by 16.1% and 12.7% respectively during the rainy season.[6]

Probio DR10TM~ may increase the population of beneficial gut microflora of Bifidobacterium and Lactobacillus.[4][7][8]

Probio DR10TM~ has also been shown to help maintain a healthy/normal gut microbiota against the aging process by competing with and excluding harmful pathogens, operating at both taxonomical and functional levels.[4]

Maintenance of intestinal barrier functions

Probio DR10TM~ helps maintain the integrity of the gut epithelium, which is a layer of cells lining the inner surface of the intestine.[4] Probio DR10TM~ also helps regulate the host immune defence against pathogens.[4]

A 2010 study also found that combining Probio DR10TM~ with an oligosaccharide prebiotics results in a decrease in the incidence of dysentery.[5]

Regulation of gut motility and improvement of gastrointestinal symptoms

Probio DR10TM~ has demonstrated a positive effect on individuals suffering from constipation.[4] A New Zealand study involving 100 adults with functional gastrointestinal symptoms showed that the supplementation of Probio DR10TM~ for 2 weeks alleviated constipation by reducing the gut transit time.[9]

Reductions in the frequency of other functional gastrointestinal symptoms, including vomiting, regurgitation, abdominal pain, nausea, gurgling, irregular bowel movements, diarrhea, and flatulence were also observed in the same study.[9]

Probio DR10TM~ may potentially divert colon fermentation towards the production of non-gaseous end products.[4] This characteristic of Probio DR10TM~ may support tolerance for the fermentation of oligosaccharides within the body, which aligns with clinical findings that Probio DR10TM~ reduces the occurrence of flatulence.[4]

Support for digestion

The fermentation of Probio DR10TM~ produces lactate and short-chain fatty acids (SCFAs) such as acetate, indicating their potential involvement in the digestion of dietary elements, without distinguishing between their source, whether it be carbohydrates or proteins.[4]

Not all probiotics are the same

Studies have shown that not all probiotics are equally effective.[10] The efficacy of probiotics is strain-specific.[10] Therefore, the recommendations of probiotics should tie specific strains to the health benefits as shown in the human studies.[11]

Mechanism of action change

Probio DR10TM~ demonstrates an excellent ability to adhere to epithelial cells, a strong capacity to endure and survive in a low pH environment, resistance to bile salts as well as the ability to modulate the immune response.[3]

Studies indicate that this strain acts on intercellular junctions, especially tight junctions.[3] Tight junctions are situated in the most apical part of the cell and consist of two key proteins, claudin and occludin.[3] These proteins play a crucial role in establishing the epithelial barrier, which acts as a safeguard against the entry of macromolecules, including lipids and proteins.[3]

These junctions are vital for controlling the permeability of the epithelium.[3] Any changes in their function can lead to increased inflammation, and subsequently, the development of diseases.[3][12]

Safety change

The presence of Bifidobacterium animalis subsp. lactis in human food has been documented since 1980, but it was likely part of human diets before that.[4]

The China National Center for Food Safety Risk Assessment (CFSA) has also approved the use of B. lactis in food for the general and paediatric population.[13]

A 2018 study found that Probio DR10TM~ is well-tolerated in adults and did not induce changes in physical activity, food intake, or body weight.[14] Probio DR10TM~ also has an established safety data in pregnant and lactating women as shown in studies.[15][16]

References change

  1. ↑ "Development and commercialisation of Fonterra's probiotic strains - ProQuest". www.proquest.com. Retrieved 2023-12-26.
  2. ↑ "Google Scholar". scholar.google.com.pk. Retrieved 2023-12-26.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Araujo, Lisa Danielly Curcino; Furlaneto, Flávia Aparecida Chaves; da Silva, Léa Assed Bezerra; Kapila, Yvonne L. (2022-08-19). "Use of the Probiotic Bifidobacterium animalis subsp. lactis HN019 in Oral Diseases". International Journal of Molecular Sciences. 23 (16): 9334. doi:10.3390/ijms23169334. ISSN 1422-0067. PMC 9409207. PMID 3601259.
  4. ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 Cheng, Jing; Laitila, Arja; Ouwehand, Arthur C. (2021-12-14). "Bifidobacterium animalis subsp. lactis HN019 Effects on Gut Health: A Review". Frontiers in Nutrition. 8. doi:10.3389/fnut.2021.790561. ISSN 2296-861X. PMC 8712437. PMID 34970580.
  5. ↑ 5.0 5.1 Sazawal, Sunil; Dhingra, Usha; Hiremath, Girish; Sarkar, Archana; Dhingra, Pratibha; Dutta, Arup; Verma, Priti; Menon, Venugopal P.; Black, Robert E. (2010-08-13). Belizan, Jose M. (ed.). "Prebiotic and Probiotic Fortified Milk in Prevention of Morbidities among Children: Community-Based, Randomized, Double-Blind, Controlled Trial". PLoS ONE. 5 (8): e12164. doi:10.1371/journal.pone.0012164. ISSN 1932-6203. PMC 2921405. PMID 20730056.
  6. ↑ Hemalatha, R. (2014-01-10). "A Community-based Randomized Double Blind Controlled Trial of Lactobacillus paracasei and Bifidobacterium lactis on Reducing Risk for Diarrhea and Fever in Preschool Children in an Urban Slum in India". European Journal of Nutrition & Food Safety. 4 (4): 325–341. doi:10.9734/EJNFS/2014/8280.
  7. ↑ Gopal, Pramod K; Prasad, Jaya; Gill, Harsharnjit S. "Effects of the consumption of Bifidobacterium lactis HN019 (DR10TM) and galacto-oligosaccharides on the microflora of the gastrointestinal tract in human subjects". Nutrition Research. 23 (10): 1313–1328. doi:10.1016/S0271-5317(03)00134-9.
  8. ↑ Ahmed, M.; Prasad, J.; Gill, H.; Stevenson, L.; Gopal, P. (2007). "Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects". The Journal of Nutrition, Health & Aging. 11 (1): 26–31. ISSN 1279-7707. PMID 17315077.
  9. ↑ 9.0 9.1 Waller, Philip A; Gopal, Pramod K.; Leyer, Gregory J; Ouwehand, Arthur C.; Reifer, Cheryl; Stewart, Morgan E.; Miller, Larry E. "Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults". Scandinavian Journal of Gastroenterology. 46 (9): 1057–1064. doi:10.3109/00365521.2011.584895. ISSN 0036-5521. PMC 3171707. PMID 21663486.
  10. ↑ 10.0 10.1 McFarland, Lynne V.; Evans, Charlesnika T.; Goldstein, Ellie J. C. (2018-05-07). "Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis". Frontiers in Medicine. 5. doi:10.3389/fmed.2018.00124. ISSN 2296-858X. PMC 5949321. PMID 29868585.
  11. ↑ "World Gastroenterology Organisation (WGO)". World Gastroenterology Organisation (WGO). Retrieved 2023-12-26.
  12. ↑ EFSA Panel on Nutrition, Novel foods and Food Allergens (NDA); Turck, Dominique; Castenmiller, Jacqueline; De Henauw, Stefaan; Hirsch‐Ernst, Karen Ildico; Kearney, John; Knutsen, Helle Katrine; Maciuk, Alexandre; Mangelsdorf, Inge; McArdle, Harry J; Naska, Androniki. "Bifidobacterium animalis subsp. lactis Bi‐07 contributes to increasing lactose digestion: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006". EFSA Journal. 18 (7). doi:10.2903/j.efsa.2020.6198. PMC 7388145. PMID 32742434.
  13. ↑ "China National Center for Food Safety Risk Assessment" (PDF). Archived from the original (PDF) on 2022-01-27. Retrieved 2024-01-29.
  14. ↑ Ibarra, Alvin; Latreille-Barbier, Mathilde; Donazzolo, Yves; Pelletier, Xavier; Ouwehand, Arthur C. (2018-05-04). "Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial". Gut Microbes. 9 (3): 236–251. doi:10.1080/19490976.2017.1412908. ISSN 1949-0976. PMC 6219592. PMID 29227175.
  15. ↑ Wibowo, Noroyono; Bardosono, Saptawati; Irwinda, Rima. "Effects of Bifidobacterium animalis lactis HN019 (DR10TM), inulin, and micronutrient fortified milk on faecal DR10TM, immune markers, and maternal micronutrients among Indonesian pregnant women". Asia Pacific Journal of Clinical Nutrition. 25 (Suppl 1): S102–S110. doi:10.6133/apjcn.122016.s2. ISSN 0964-7058. PMID 28027638.
  16. ↑ Prescott, S. L.; Wickens, K.; Westcott, L.; Jung, W.; Currie, H.; Black, P. N.; Stanley, T. V.; Mitchell, E. A.; Fitzharris, P.; Siebers, R.; Wu, L. "Supplementation with Lactobacillus rhamnosus or Bifidobacterium lactis probiotics in pregnancy increases cord blood interferon-gamma and breast milk transforming growth factor-beta and immunoglobin A detection". Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology. 38 (10): 1606–1614. doi:10.1111/j.1365-2222.2008.03061.x. ISSN 1365-2222. PMID 18631345.
Retrieved from "https://simple.wikipedia.org/w/index.php?title=Probio_DR10&oldid=9411690"